Boehringer Ingelheim India Pvt. Ltd.
Boehringer Ingelheim India Pvt. Ltd., a subsidiary of the global pharmaceutical giant Boehringer Ingelheim, is headquartered in India and operates extensively across the country. Founded in 1885, the company has established itself as a leader in the pharmaceutical industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim India offers a diverse range of core products, including prescription medicines and vaccines that address critical health challenges. The company is renowned for its research-driven approach, which has led to significant advancements in therapeutic areas such as respiratory diseases, oncology, and diabetes care. Boehringer Ingelheim India has achieved notable market recognition, consistently ranking among the top pharmaceutical companies in the region. Its dedication to improving patient outcomes and enhancing animal health underscores its pivotal role in the healthcare landscape.
DitchCarbon Score
How does Boehringer Ingelheim India Pvt. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim India Pvt. Ltd.'s score of 19 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim India Pvt. Ltd.'s reported carbon emissions
Boehringer Ingelheim India Pvt. Ltd. currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no documented reduction targets or climate commitments outlined in their initiatives. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and climate action, often setting ambitious targets to reduce their carbon footprint. While Boehringer Ingelheim India may not have publicly stated their specific commitments or targets at this time, the industry trend indicates a growing emphasis on reducing Scope 1, 2, and 3 emissions to combat climate change. As the company progresses, it may adopt strategies aligned with global climate initiatives, potentially including science-based targets and pledges to enhance their environmental performance.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim India Pvt. Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
